{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:07:24Z","timestamp":1777860444148,"version":"3.51.4"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.2169\/internalmedicine.5000-20","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T22:15:57Z","timestamp":1601504157000},"page":"2343-2351","source":"Crossref","is-referenced-by-count":6,"title":["The Efficacy of Medium- to Long-term Anti-TNF-\u03b1 Antibody-based Maintenance Therapy in Beh\u00e7et's Disease Patients with Intestinal Lesions"],"prefix":"10.2169","volume":"59","author":[{"given":"Harutaka","family":"Kambayashi","sequence":"first","affiliation":[{"name":"Institute of Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Omori","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Saito","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Murasugi","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kashiwagi","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsutoshi","family":"Tokushige","sequence":"additional","affiliation":[{"name":"Institute of Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Hashimoto T. Behcet's disease. J Jpn Soc Intern Med 91: 94-98, 2012."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ishigatsubo Y, Samukawa S. Behcet's disease from the aspect of autoinflammatory disease. Jpn J Clin Immunol 34: 408-419, 2011.","DOI":"10.2177\/jsci.34.408"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Saadoun D, Wechsler B. Beh\u00e7et's disease. Orphanet J Rare Dis 7: 20, 2012.","DOI":"10.1186\/1750-1172-7-20"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 3: e297, 2006.","DOI":"10.1371\/journal.pmed.0030297"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Beh\u00e7et's disease. Nat Genet 42: 698-702, 2010.","DOI":"10.1038\/ng.625"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tong B, Liu X, Xiao J, Su G. Immunopathogenesis of Behcet's disease. Front Immunol 10: 665, 2019.","DOI":"10.3389\/fimmu.2019.00665"},{"key":"7","unstructured":"7. Matsuda T. Guidebook for Beh\u00e7et's Disease. Nihonigakukan, Tokyo, 2002 (in Japanese)."},{"key":"8","unstructured":"8. Kobashikawa T, Nanke Y, Oda H, Yamanaka H, Kotake S. Bowel lesions of Behcet's disease are frequently detected in non-ileocecal regions as well as in the ileocecum: clinical features of 51 Japanese patients with Bechet's disease. J Tokyo Wom Med Univ 80: 132-138, 2010."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Park YE, Cheon JH. Updated therapy for intestinal Beh\u00e7et's disease. Korean J Intern Med 33: 1-19, 2018.","DOI":"10.3904\/kjim.2017.377"},{"key":"10","first-page":"60","volume":"53","author":"M Kurata","year":"2006","unstructured":"10. Kurata M, Nozue M, Seino K, Murata H, Sumita T, Katashi F. Indications for surgery in intestinal Beh\u00e7et's disease. Hepatogastroenterology 53: 60-63, 2006.","journal-title":"Hepatogastroenterology","ISSN":"https:\/\/id.crossref.org\/issn\/0172-6390","issn-type":"print"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Travis SPL, Czajkowski M, McGovern DPB, Watson RGP, Bell AL. Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49: 725-728, 2001.","DOI":"10.1136\/gut.49.5.725"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet's disease. Inflamm Bowel Dis 14: 1259-1264, 2008.","DOI":"10.1002\/ibd.20457"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol 13: 940-948.e3, 2015.","DOI":"10.1016\/j.cgh.2014.08.042"},{"key":"14","unstructured":"14. Transforming Vesalius: The 16th-Century Scientific Revolution Brought to Life for the 21st Century. Karger Publishers, Basel [Internet]. [cited 2013 Feb 4]. Available from: http:\/\/www-user.yokohama-cu.ac.jp\/\u02dcbehcet\/patient\/behcet\/standerd.html (in Japanese)"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Inoue N, Kobayashi K, Naganuma M, et al. Long-term safety and efficacy of adalimumab for intestinal Behcet's disease in the open label study following a phase 3 clinical trial. Intest Res 15: 395-401, 2017.","DOI":"10.5217\/ir.2017.15.3.395"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of inflix-imab in patients with intestinal Beh\u00e7et's disease refractory to conventional medication. Intern Med 52: 1855-1862, 2013.","DOI":"10.2169\/internalmedicine.52.0589"},{"key":"17","unstructured":"17. Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Beh\u00e7et's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis 19: 1833-1838, 2013."},{"key":"18","unstructured":"18. Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95: e3863, 2016."},{"key":"19","unstructured":"19. Vitale A, Emmi G, Lopalco G, et al. Adalimumab effectiveness in Behcet's disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol 36: 451-455, 2017."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121: 785-796, 2014.","DOI":"10.1016\/j.ophtha.2013.09.048"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kaikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behcet's syndrome. J Neurol Sci 272: 99-105, 2008.","DOI":"10.1016\/j.jns.2008.05.002"},{"key":"22","unstructured":"22. Almoznino G, Ben-Chetrit E. Infliximab for the treatment of resistant oral ulcers in Beh\u00e7et's disease: a case report and review of the literature. Clin Exp Rheumatol 25(Suppl): S99-S102, 2007."},{"key":"23","doi-asserted-by":"crossref","unstructured":"24. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. Rheumatology 46: 736-741, 2007.","DOI":"10.1093\/rheumatology\/kem034"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25. Vitale A, Rigante D, Lopalco G, et al. New therapeutic solutions for Behcet's syndrome. Expert Opin Investig Drugs 25: 827-840, 2016.","DOI":"10.1080\/13543784.2016.1181751"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26. Askling J, Van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 60: 3180-3189, 2009.","DOI":"10.1002\/art.24941"},{"key":"26","doi-asserted-by":"publisher","unstructured":"27. Andersen NN, Pasternak B, Basit S, et al. Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 311: 2406-2413, 2014.","DOI":"10.1001\/jama.2014.5613"},{"key":"27","unstructured":"28. Ohyama T, Yoshikawa T, Yasukawa J, Akahori T, Inatsugu N. A case report of intestinal Behcet's disease without clinical progress for long term. J Nara Med Assoc 55: 175-181, 2004."},{"key":"28","unstructured":"29. Kosaka E, Matsushita I, Sugiyama E, et al. Adverse events associated with infliximab therapy for rheumatoid arthritis. Rinsho Seikei Geka 41: 1177-1181, 2006 (In Japanese)."},{"key":"29","unstructured":"30. Gisbert JP, Marin AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: Systematic review and meta-analysis. Am J Gastroenterol 111: 632-647, 2016."},{"key":"30","unstructured":"31. Fiorino G, Cortes PN, Ellul P, et al. Discontinuation of infliximab in patients with ulcerative colitis is associated with increased risk of relapse: a multinational retrospective cohort study. Clin Gastroenterol Hepatol 14: 1426-1432, 2016."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/19\/59_5000-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T03:55:14Z","timestamp":1601697314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/19\/59_5000-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":30,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5000-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}